{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:55:23Z","timestamp":1790855723531,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000093","name":"U.S. Department of Health & Human Services | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["5R01HL167232"],"award-info":[{"award-number":["5R01HL167232"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76972-9","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T19:34:23Z","timestamp":1788204863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IFN-\u03b3-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Sae Bom","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-8706","authenticated-orcid":false,"given":"Allan","family":"Pavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan","family":"Beatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8936-0470","authenticated-orcid":false,"given":"Justin C.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay K.","family":"Mandula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Roselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwin C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-2268","authenticated-orcid":false,"given":"Rachel V.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6001-0636","authenticated-orcid":false,"given":"Hiroshi","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-5971","authenticated-orcid":false,"given":"Julio","family":"Vazquez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Goala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Ilecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8055-588X","authenticated-orcid":false,"given":"Cooper J.","family":"Sailer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2538-9983","authenticated-orcid":false,"given":"Shannon L.","family":"McSain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Showkat","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8495-8480","authenticated-orcid":false,"given":"Muhammad Junaid","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-3867","authenticated-orcid":false,"given":"Rosa A.","family":"Sierra-Mondragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-1762","authenticated-orcid":false,"given":"John M.","family":"Koomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6146-2047","authenticated-orcid":false,"given":"Jonathan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9316-1924","authenticated-orcid":false,"given":"Timothy I.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5775-408X","authenticated-orcid":false,"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-0409","authenticated-orcid":false,"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Abraham-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith L.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-6566","authenticated-orcid":false,"given":"Paulo C.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1149-0880","authenticated-orcid":false,"given":"Yun Pyo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-3065","authenticated-orcid":false,"given":"Marco L.","family":"Davila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"76972_CR1","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med"},{"key":"76972_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med"},{"key":"76972_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med"},{"key":"76972_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med"},{"key":"76972_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med"},{"key":"76972_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke, F. L. et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25, 285\u2013295 (2017).","journal-title":"Mol. Ther."},{"key":"76972_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med"},{"key":"76972_CR8","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med"},{"key":"76972_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"76972_CR10","doi-asserted-by":"publisher","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol, https:\/\/doi.org\/10.1038\/s41571-023-00754-1 (2023).","DOI":"10.1038\/s41571-023-00754-1"},{"key":"76972_CR11","doi-asserted-by":"publisher","unstructured":"Roselli, E. Faramand, R. & Davila, M. L. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI142030 (2021).","DOI":"10.1172\/JCI142030"},{"key":"76972_CR12","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"76972_CR13","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean, E. A. et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 3268\u20133276 (2020).","journal-title":"Blood Adv."},{"key":"76972_CR14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702\u2013723 (2020).","journal-title":"Cancer Discov."},{"key":"76972_CR15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood.2021010930","volume":"138","author":"V Plaks","year":"2021","unstructured":"Plaks, V. et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138, 1081\u20131085 (2021).","journal-title":"Blood"},{"key":"76972_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1182\/blood.2021015008","volume":"140","author":"MD Jain","year":"2022","unstructured":"Jain, M. D. et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood 140, 491\u2013503 (2022).","journal-title":"Blood"},{"key":"76972_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval, R. et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 40, 369\u2013381 (2022).","journal-title":"J. Clin. Oncol."},{"key":"76972_CR18","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878\u20131887 (2020).","journal-title":"Nat. Med"},{"key":"76972_CR19","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","volume":"12","author":"Z Jackson","year":"2022","unstructured":"Jackson, Z. et al. Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma. Cancer Discov. 12, 1886\u20131903 (2022).","journal-title":"Cancer Discov."},{"key":"76972_CR20","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621\u20132633 (2021).","journal-title":"Blood"},{"key":"76972_CR21","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler, N. et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat. Med 28, 1872\u20131882 (2022).","journal-title":"Nat. Med"},{"key":"76972_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott, D. W. & Gascoyne, R. D. The tumour microenvironment in B cell lymphomas. Nat. Rev. Cancer 14, 517\u2013534 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"76972_CR23","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","volume":"39","author":"CB Steen","year":"2021","unstructured":"Steen, C. B. et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell 39, 1422\u20131437 e1410 (2021).","journal-title":"Cancer Cell"},{"key":"76972_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799\u2013820 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"76972_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med 24, 731\u2013738 (2018).","journal-title":"Nat. Med"},{"key":"76972_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85\u201396 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"76972_CR27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med"},{"key":"76972_CR28","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","volume":"186","author":"DJ Kloosterman","year":"2023","unstructured":"Kloosterman, D. J. & Akkari, L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell 186, 1627\u20131651 (2023).","journal-title":"Cell"},{"key":"76972_CR29","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides, A. et al. The complex role of tumor-infiltrating macrophages. Nat. Immunol. 23, 1148\u20131156 (2022).","journal-title":"Nat. Immunol."},{"key":"76972_CR30","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","volume":"189","author":"DH Munn","year":"1999","unstructured":"Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363\u20131372 (1999).","journal-title":"J. Exp. Med"},{"key":"76972_CR31","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","volume":"64","author":"PC Rodriguez","year":"2004","unstructured":"Rodriguez, P. C. et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839\u20135849 (2004).","journal-title":"Cancer Res"},{"key":"76972_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"76972_CR33","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"76972_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/2326-6066.CIR-20-0253","volume":"9","author":"JC Boucher","year":"2021","unstructured":"Boucher, J. C. et al. CD28 costimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function. Cancer Immunol. Res. 9, 62\u201374 (2021).","journal-title":"Cancer Immunol. Res"},{"key":"76972_CR35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nri1668","volume":"5","author":"V Bronte","year":"2005","unstructured":"Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5, 641\u2013654 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"76972_CR36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1006\/niox.1999.0255","volume":"3","author":"JP Tenu","year":"1999","unstructured":"Tenu, J. P. et al. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide 3, 427\u2013438 (1999).","journal-title":"Nitric Oxide"},{"key":"76972_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","volume":"222","author":"PC Rodriguez","year":"2008","unstructured":"Rodriguez, P. C. & Ochoa, A. C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222, 180\u2013191 (2008).","journal-title":"Immunol. Rev."},{"key":"76972_CR38","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1021\/jm00049a007","volume":"37","author":"WM Moore","year":"1994","unstructured":"Moore, W. M. et al. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J. Med Chem. 37, 3886\u20133888 (1994).","journal-title":"J. Med Chem."},{"key":"76972_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.tcb.2020.03.002","volume":"30","author":"IS Harris","year":"2020","unstructured":"Harris, I. S. & DeNicola, G. M. The complex interplay between antioxidants and ROS in cancer. Trends Cell Biol. 30, 440\u2013451 (2020).","journal-title":"Trends Cell Biol."},{"key":"76972_CR40","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","volume":"11","author":"D Alizadeh","year":"2021","unstructured":"Alizadeh, D. et al. IFNgamma is critical for CAR T cell-mediated myeloid activation and induction of endogenous immunity. Cancer Discov. 11, 2248\u20132265 (2021).","journal-title":"Cancer Discov."},{"key":"76972_CR41","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","volume":"3","author":"SR Bailey","year":"2022","unstructured":"Bailey, S. R. et al. Blockade or deletion of IFNgamma reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discov. 3, 136\u2013153 (2022).","journal-title":"Blood Cancer Discov."},{"key":"76972_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava, S. et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell 39, 193\u2013208 e110 (2021).","journal-title":"Cancer Cell"},{"key":"76972_CR43","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1101\/gad.1881410","volume":"24","author":"N Takeda","year":"2010","unstructured":"Takeda, N. et al. Differential activation and antagonistic function of HIF-alpha isoforms in macrophages are essential for NO homeostasis. Genes Dev. 24, 491\u2013501 (2010).","journal-title":"Genes Dev."},{"key":"76972_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","volume":"12","author":"B Keith","year":"2011","unstructured":"Keith, B., Johnson, R. S. & Simon, M. C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9\u201322 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"76972_CR45","doi-asserted-by":"publisher","first-page":"F1171","DOI":"10.1152\/ajprenal.00507.2010","volume":"300","author":"R Hodeify","year":"2011","unstructured":"Hodeify, R., Tarcsafalvi, A., Megyesi, J., Safirstein, R. L. & Price, P. M. Cdk2-dependent phosphorylation of p21 regulates the role of Cdk2 in cisplatin cytotoxicity. Am. J. Physiol. Ren. Physiol. 300, F1171\u2013F1179 (2011).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"76972_CR46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41423-021-00792-8","volume":"19","author":"JM Marchingo","year":"2022","unstructured":"Marchingo, J. M. & Cantrell, D. A. Protein synthesis, degradation, and energy metabolism in T cell immunity. Cell Mol. Immunol. 19, 303\u2013315 (2022).","journal-title":"Cell Mol. Immunol."},{"key":"76972_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nri.2017.99","volume":"18","author":"GR Bantug","year":"2018","unstructured":"Bantug, G. R., Galluzzi, L., Kroemer, G. & Hess, C. The spectrum of T cell metabolism in health and disease. Nat. Rev. Immunol. 18, 19\u201334 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"76972_CR48","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41577-021-00537-8","volume":"21","author":"M Reina-Campos","year":"2021","unstructured":"Reina-Campos, M., Scharping, N. E. & Goldrath, A. W. CD8(+) T cell metabolism in infection and cancer. Nat. Rev. Immunol. 21, 718\u2013738 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"76972_CR49","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s42255-022-00676-9","volume":"4","author":"H Zhao","year":"2022","unstructured":"Zhao, H. et al. Myeloid-derived itaconate suppresses cytotoxic CD8(+) T cells and promotes tumour growth. Nat. Metab. 4, 1660\u20131673 (2022).","journal-title":"Nat. Metab."},{"key":"76972_CR50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature25986","volume":"556","author":"EL Mills","year":"2018","unstructured":"Mills, E. L. et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature 556, 113\u2013117 (2018).","journal-title":"Nature"},{"key":"76972_CR51","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke, F. L. et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat. Med. 30, 507\u2013518 (2024).","journal-title":"Nat. Med"},{"key":"76972_CR52","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Macrophages in immunoregulation and therapeutics. Signal Transduct. Target Ther. 8, 207 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"76972_CR53","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/jso.20372","volume":"94","author":"CN Chen","year":"2006","unstructured":"Chen, C. N., Hsieh, F. J., Cheng, Y. M., Chang, K. J. & Lee, P. H. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer. J. Surg. Oncol. 94, 226\u2013233 (2006).","journal-title":"J. Surg. Oncol."},{"key":"76972_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cell.2011.06.006","volume":"146","author":"CE Eyler","year":"2011","unstructured":"Eyler, C. E. et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 146, 53\u201366 (2011).","journal-title":"Cell"},{"key":"76972_CR55","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1172\/JCI42059","volume":"120","author":"SA Glynn","year":"2010","unstructured":"Glynn, S. A. et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J. Clin. Invest 120, 3843\u20133854 (2010).","journal-title":"J. Clin. Invest"},{"key":"76972_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0527-x","volume":"17","author":"S Granados-Principal","year":"2015","unstructured":"Granados-Principal, S. et al. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Res. 17, 25 (2015).","journal-title":"Breast Cancer Res"},{"key":"76972_CR57","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.immuni.2014.04.006","volume":"40","author":"M Watanabe","year":"2014","unstructured":"Watanabe, M., Moon, K. D., Vacchio, M. S., Hathcock, K. S. & Hodes, R. J. Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses. Immunity 40, 681\u2013691 (2014).","journal-title":"Immunity"},{"key":"76972_CR58","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2011.09.021","volume":"35","author":"R Wang","year":"2011","unstructured":"Wang, R. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871\u2013882 (2011).","journal-title":"Immunity"},{"key":"76972_CR59","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med"},{"key":"76972_CR60","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380\u2013390 (2016).","journal-title":"Immunity"},{"key":"76972_CR61","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg0654","volume":"9","author":"YJ Chen","year":"2023","unstructured":"Chen, Y. J. et al. Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy. Sci. Adv. 9, eadg0654 (2023).","journal-title":"Sci. Adv."},{"key":"76972_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102164","volume":"47","author":"AD Read","year":"2021","unstructured":"Read, A. D., Bentley, R. E., Archer, S. L. & Dunham-Snary, K. J. Mitochondrial iron-sulfur clusters: Structure, function, and an emerging role in vascular biology. Redox Biol. 47, 102164 (2021).","journal-title":"Redox Biol."},{"key":"76972_CR63","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature11986","volume":"496","author":"GM Tannahill","year":"2013","unstructured":"Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 496, 238\u2013242 (2013).","journal-title":"Nature"},{"key":"76972_CR64","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher, A. M., Workman, C. J. & Vignali, D. A. A. Interferon-gamma: teammate or opponent in the tumour microenvironment?. Nat. Rev. Immunol. 22, 158\u2013172 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"76972_CR65","doi-asserted-by":"publisher","unstructured":"Boulch, M. et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol https:\/\/doi.org\/10.1126\/sciimmunol.abd4344 (2021).","DOI":"10.1126\/sciimmunol.abd4344"},{"key":"76972_CR66","doi-asserted-by":"publisher","unstructured":"Boulch, M. et al. Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-gamma is a major determinant of CD4(+) CAR T-cell antitumor activity. Nat Cancer. https:\/\/doi.org\/10.1038\/s43018-023-00570-7 (2023).","DOI":"10.1038\/s43018-023-00570-7"},{"key":"76972_CR67","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","volume":"604","author":"RC Larson","year":"2022","unstructured":"Larson, R. C. et al. CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours. Nature 604, 563\u2013570 (2022).","journal-title":"Nature"},{"key":"76972_CR68","doi-asserted-by":"publisher","unstructured":"Goala, P. et al. IFN-gamma-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI194631 (2026).","DOI":"10.1172\/JCI194631"},{"key":"76972_CR69","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","volume":"7","author":"MR Schuelke","year":"2023","unstructured":"Schuelke, M. R. et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 7, 5603\u20135607 (2023).","journal-title":"Blood Adv."},{"key":"76972_CR70","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","volume":"26","author":"R Faramand","year":"2020","unstructured":"Faramand, R. et al. Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. Clin. Cancer Res. 26, 4823\u20134831 (2020).","journal-title":"Clin. Cancer Res"},{"key":"76972_CR71","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2643-3230.BCD-23-0056","volume":"5","author":"RG Faramand","year":"2024","unstructured":"Faramand, R. G. et al. Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma. Blood Cancer Discov. 5, 106\u2013113 (2024).","journal-title":"Blood Cancer Discov."},{"key":"76972_CR72","doi-asserted-by":"publisher","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","volume":"8","author":"ML Davila","year":"2013","unstructured":"Davila, M. L., Kloss, C. C., Gunset, G. & Sadelain, M. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One 8, e61338 (2013).","journal-title":"PLoS One"},{"key":"76972_CR73","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","volume":"318","author":"JM Adams","year":"1985","unstructured":"Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533\u2013538 (1985).","journal-title":"Nature"},{"key":"76972_CR74","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1084\/jem.167.2.353","volume":"167","author":"AW Harris","year":"1988","unstructured":"Harris, A. W. et al. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 167, 353\u2013371 (1988).","journal-title":"J. Exp. Med"},{"key":"76972_CR75","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.4049\/jimmunol.177.10.7303","volume":"177","author":"FO Martinez","year":"2006","unstructured":"Martinez, F. O., Gordon, S., Locati, M. & Mantovani, A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177, 7303\u20137311 (2006).","journal-title":"J. Immunol."},{"key":"76972_CR76","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","volume":"23","author":"L Cassetta","year":"2023","unstructured":"Cassetta, L. & Pollard, J. W. A timeline of tumour-associated macrophage biology. Nat. Rev. Cancer 23, 238\u2013257 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"76972_CR77","doi-asserted-by":"publisher","unstructured":"Singhal, S. et al. Human tumor-associated monocytes\/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aat1500 (2019).","DOI":"10.1126\/scitranslmed.aat1500"},{"key":"76972_CR78","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cmet.2020.12.007","volume":"33","author":"YP Kang","year":"2021","unstructured":"Kang, Y. P. et al. Non-canonical glutamate-cysteine ligase activity protects against ferroptosis. Cell Metab. 33, 174\u2013189.e177 (2021).","journal-title":"Cell Metab."},{"key":"76972_CR79","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.1093\/bioinformatics\/btz209","volume":"35","author":"P Millard","year":"2019","unstructured":"Millard, P. et al. IsoCor: isotope correction for high-resolution MS labeling experiments. Bioinformatics 35, 4484\u20134487 (2019).","journal-title":"Bioinformatics"},{"key":"76972_CR80","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1535-7163.MCT-24-1091","volume":"24","author":"L Chen","year":"2025","unstructured":"Chen, L. et al. PROTAC-mediated degradation of TAF1 induces apoptosis in AML cells and inhibits tumor growth in vivo. Mol. Cancer Ther. 24, 1712\u20131721 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"76972_CR81","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/1878-0261.70155","volume":"20","author":"J Son","year":"2026","unstructured":"Son, J. et al. Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells. Mol. Oncol. 20, 1041\u20131060 (2026).","journal-title":"Mol. Oncol."},{"key":"76972_CR82","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367\u20131372 (2008).","journal-title":"Nat. Biotechnol."},{"key":"76972_CR83","unstructured":"Blighe, K., Lewis, M., Lun, A. & Blighe, M. K. Package \u2018PCAtools.\u2019 REAGENT or (2019)."},{"key":"76972_CR84","unstructured":"Smyth, G. K. in Bioinformatics and cOmputational Biology Solutions Using R and Bioconductor 397\u2013420 (Springer, 2005)."},{"key":"76972_CR85","doi-asserted-by":"crossref","unstructured":"Kuznetsova, A., Brockhoff, P. B. & Christensen, R. H. B. lmerTest package: tests in linear mixed effects models. J. Stat. Softw. 82, 1\u201326 (2017).","DOI":"10.18637\/jss.v082.i13"},{"key":"76972_CR86","first-page":"2","volume":"12","author":"D Bates","year":"2015","unstructured":"Bates, D. et al. Package \u2018lme4\u2019. convergence 12, 2 (2015).","journal-title":"convergence"},{"key":"76972_CR87","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics: a J. Integr. Biol. 16, 284\u2013287 (2012).","journal-title":"Omics: a J. Integr. Biol."},{"key":"76972_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GX Zheng","year":"2017","unstructured":"Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).","journal-title":"Nat. Commun."},{"key":"76972_CR89","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529 (2021).","journal-title":"Cell"},{"key":"76972_CR90","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76972-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76972-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76972-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:03:26Z","timestamp":1790852606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76972-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76972"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76972-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3481746\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.L.D. has received research funding from Kite\/Gilead. M.L.D. has also received research funding from Novartis, CRISPR, and Bristol Myers Squibb (BMS) that are unrelated to this work. M.L.D. has received consulting fees or honoraria from Adicet, Kite, BMS, A2 Biotherapeutics, Legend, Janssen (J&J), Synthekine, Bellicum, Capstan, and CARGO. M.L.D. holds stock or stock options in Adaptive Biotechnologies, A2 Biotherapeutics, and Adicet. M.L.D. has intellectual property relevant to this work and has licensed CAR technology to CRISPR and Atara. M.H. has received consultancy fees, speaker\u2019s bureau honoraria, and\/or other compensation from Adaptive Biotechnologies, Amgen, Aptitude Health, Blueprint Oncology, Celgene, Decibio, Diaceutics, Guidepoint, Seattle Genetics, Stemline, Tegus, Janssen, and BMS. J.M.K. has been funded by a sponsored research agreement with Bristol Myers Squibb unrelated to this project. M.D.J. has served in consultancy or advisory roles for Kite\/Gilead, Myeloid Therapeutics, and Allogene. He has received research funding from Kite\/Gilead and the Florida Academic Cancer Center Alliance (FACCA). M.D.J. has also received research funding from Loxo@Lilly, Incyte, the Mark Foundation, and the Bankhead-Coley Cancer Research Program unrelated to this project. F.L.L. has research funding from Kite Pharma. He also has financial and professional relationships with following organizations that are unrelated to this work: consulting or scientific advisory roles with A2, Allogene, Amgen, Bluebird Bio, BMS\/Celgene, Calibr, Caribou, Cellular Biomedicine Group, Cowen, Daiichi Sankyo, EcoR1, Emerging Therapy Solutions, GammaDelta Therapeutics, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Takeda, Wugen, Umoja, and Pfizer; research contracts or grants to his institution from Kite Pharma, Allogene, CERo Therapeutics, Novartis, Bluebird Bio, 2SeventyBio, BMS, the National Cancer Institute (PI), and the Leukemia and Lymphoma Society (PI); patents and other intellectual property (unlicensed) in the field of cellular immunotherapy; and educational or editorial activities with Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, and the Society for Immunotherapy of Cancer. R.F. has received research funding from Kite\/Gilead. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10375"}}